SCHEMBL1067154

SCHEMBL1067154

CN1CCN(C(=O)Nc2ccc(C(=O)O)cc2)CC1

nearest known ligand 0.69

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.69
SMN1; SMN2 Q16637 3/20 0.56
ALDH1A1 P00352 2/20 0.56
MAPT P10636 4/20 0.55
EPHX2 P34913 2/20 0.54
LMNA P02545 2/20 0.54
NAMPT P43490 1/20 0.54
POLB P06746 2/20 0.53
ABL1 P00519 1/20 0.53
RIN1 Q13671 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4300084 0.85 KDM4E (0.93) KDM4ESMN1; SMN2ALDH1A1MAPTPOLB
SCHEMBL178450 0.83 NPC1 (0.73) KDM4ESMN1; SMN2ALDH1A1MAPTLMNA
SCHEMBL3568415 0.82 KDM4E (0.67) KDM4ESMN1; SMN2ALDH1A1MAPTLMNA
SCHEMBL10053027 0.82 KMT2A (0.71) KDM4ESMN1; SMN2ALDH1A1MAPTEPHX2
SCHEMBL15134852 0.82 RAB9A (0.71) KDM4ESMN1; SMN2ALDH1A1MAPTLMNA
SCHEMBL13234926 0.82 LMNA (0.67) KDM4ESMN1; SMN2ALDH1A1MAPTLMNA
SCHEMBL12668375 0.81 KDM4E (0.65) KDM4ESMN1; SMN2ALDH1A1MAPTLMNA
SCHEMBL7967450 0.81 CYP2C9 (0.73) SMN1; SMN2ALDH1A1MAPTLMNANPC1
SCHEMBL223421 0.80 MAPT (0.71) KDM4ESMN1; SMN2ALDH1A1MAPTPOLB
SCHEMBL5069499 0.80 FAAH (0.54) KDM4EMAPTNAMPTPOLBABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7868205-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2011-01-11 US disclosed
US-7868205-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2011-01-11 US disclosed
US-7868205-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2011-01-11 US disclosed
US-20080132459-A1 Inhibitors of Histone Deacetylase METHYLGENE, INC. (CA) 2008-06-05 US disclosed
US-20080132459-A1 Inhibitors of Histone Deacetylase METHYLGENE, INC. (CA) 2008-06-05 US disclosed
WO-2005030705-A9 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC (CA) 2006-04-20 WO disclosed
WO-2005030704-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE, INC. (CA) 2005-04-07 WO disclosed
WO-2005030704-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE, INC. (CA) 2005-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132459-A1 Inhibitors of Histone Deacetylase HDAC1, HDAC5, HDAC3 KDM4E 123/4885SMN1; SMN2 3671/4885ALDH1A1 796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.